Second Annual Global Biomarkers Consortium Clinical Approaches to Targeted Technologies
![]() |
Part 1: Second Annual Global Biomarkers Consortium Clinical Approaches to targeted Technologies
Professor Rob Coleman/Razelle Kurzrock MDn
|
![]() |
Part 2: Taking Stock of Molecular Oncology Biomarkers: Bioinformatics
Professor Dr. Ulrich Mansmann/Professor Rob Colemank
|
![]() |
Part 3: Understanding Cancer at the Molecular Level: From Cancer Genes to Precision Medicines and Biomarkers
Paul Workman
|
![]() |
Part 4: How I treat My Patients with Metastatic Melanoma
Sanjiv S Agarwala/Lojas Pusztai
|
![]() |
Part 5: Use of Biomarkers in the Treatment of Multiple Myeloma
G. David Roodman/Christopher Sweeney/Mark Levis
|
![]() |
Part 6: Divide and Concur: Addressing Lymphoma Heterogeneity Through Biomarker-Driven Trials in Lymphoma
Anas Younes
|
![]() |
Part 7: Can You Patent Biomarkers?
Aaron Seth Kesselheim
|
![]() |
Part 8: Review of Saturday’s Presentations and Preview of Today
Jorge E. Cortes/Roy S. Herbst
|
![]() |
Part 9: How I Treat My Patients with MDS Optimal Value-Based Use of Molecular Biomarkers in Oncology
Rami Komrokji
|
![]() |
Part 10: How I Treat My Patients with Myeloproliferative Neoplasms
Francesco Passamonti
|
![]() |
Part 11: The Challenges of Biomarker-Based Clinical Trials
Roy S. Herbst/Alex A. Adjei
|
![]() |
Part 12: Use of NGS to Identify Actionable Genomic Alterations in Diverse Solid Tumor Types
Gary A. Palmer
|
![]() |
Part 13: Development of Gene-Expression Tests for Early Detection of Lung Cancer
Avrum Spira
|
![]() |
Part 14: Making Personalized Medicine a Reality: The Realization of Genomic Medicine
Scott A. Tomlins
|
![]() |
Part 15: The Future of Personalized Medicine in Oncology: Practical Considerations
Razelle Kurzrock
|
By continuing to browse this site, you agree to our
use of cookies.